News
PHAR
7.53
-2.96%
-0.23
Weekly Report: what happened at PHAR last week (1111-1115)?
Weekly Report · 5d ago
Weekly Report: what happened at PHAR last week (1104-1108)?
Weekly Report · 11/11 10:33
Weekly Report: what happened at PHAR last week (1028-1101)?
Weekly Report · 11/04 10:32
Pharming Group Price Target Cut to $30.00/Share From $31.00 by Oppenheimer
Dow Jones · 10/28 12:56
Pharming Group Is Maintained at Outperform by Oppenheimer
Dow Jones · 10/28 12:56
Oppenheimer Maintains Outperform on Pharming, Lowers Price Target to $30
Benzinga · 10/28 12:45
Pharming price target lowered to $30 from $31 at Oppenheimer
TipRanks · 10/28 12:00
Weekly Report: what happened at PHAR last week (1021-1025)?
Weekly Report · 10/28 10:26
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 10/24 19:24
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Benzinga · 10/24 19:14
Positive Outlook for Pharming Group Amidst Growth Opportunities and Leadership Transition
TipRanks · 10/24 15:05
Pharming reports Q3 results
Seeking Alpha · 10/24 08:21
BRIEF-Pharming Group On Track To Meet 2024 Total Revenue Guidance
Reuters · 10/24 05:42
Pharming Group Reaffirms 2024 Total Revenue Guidance Of $280M-$295M (14% To 20% Growth)
Benzinga · 10/24 05:42
Pharming Q3 EPS $(0.002) Misses $0.01 Estimate, Sales $74.80M Miss $76.93M Estimate
Benzinga · 10/24 05:40
BRIEF-Pharming Group 9M EPS USD -0.022
Reuters · 10/24 05:00
PHARMING GROUP NV - FIRMLY ON TRACK TO MEET OUR 2024 TOTAL REVENUE GUIDANCE
Reuters · 10/24 05:00
Weekly Report: what happened at PHAR last week (1014-1018)?
Weekly Report · 10/21 10:24
Where Pharming Stands With Analysts
Benzinga · 10/15 13:00
Analysts Offer Insights on Healthcare Companies: Pharming Group (PHAR) and MoonLake Immunotherapeutics (MLTX)
TipRanks · 10/15 10:20
More
Webull provides a variety of real-time PHAR stock news. You can receive the latest news about Pharming Group N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.